Vanta Bioscience Limited

Healthcare · Healthcare Services

BSE: 540729
₹22.62
▲ 1.07 (4.97%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
34/100
Weak
Valuation
—/100
Data unavailable
Momentum
9/100
Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
Data unavailable.
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-57.3
Free Cash Flow
₹-5 Cr
as of March 31, 2026
Industry median ₹1 Cr (75 companies)
EPS Growth (YoY)
Data unavailable.
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
Data unavailable.
Revenue Growth (YoY)
Data unavailable.
Current Ratio
1.20
as of March 31, 2026
Industry median 2.06 (74 companies)
Debt to Equity
Data unavailable (needs a filed half-yearly balance sheet).
Interest Coverage
Data unavailable.
Net Margin
-88.39%
as of Sept. 30, 2022
Industry median 9.88% (61 companies)
Operating Margin (EBIT)
-17.33%
as of Sept. 30, 2022
Industry median 17.21% (61 companies)
Operating Margin (TTM)
Data unavailable.
Return on Assets
Data unavailable.
Return on Capital Employed
Data unavailable (needs a filed half-yearly balance sheet).
Return on Equity
Data unavailable (needs a filed half-yearly balance sheet).

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

0 of 3 met
  • No Quality score is Strong (70 or more)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 1 met
  • No 1-year return beats the industry median

Value and momentum

1 of 4 met
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • Yes Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
5.0%
Low 22.2200 · High 22.6200
1W return
9.9%
Low 18.5900 · High 22.6200
1M return
15.2%
Low 18.5900 · High 22.6200
52W return
-60.0%
Low 18.5900 · High 22.8300
Lifetime High ₹195.0000 (May 2, 2019)
Lifetime Low ₹19.5600 (Sept. 24, 2026)

Full price history and technicals →

EMA & SMA

Bullish1
Bearish5
5D
21.9
10D
25.4
20D
33.6
50D
47.0
100D
53.8
200D
58.3

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

22.49
Pivot
First resistance22.75
Second resistance22.89
Third resistance23.15
First support22.35
Second support22.09
Third support21.95
Day RSI28.4
Day MFI87.6
Day MACD-10.38
Day MACD signal-9.56

Beta

1M—
3M—
1Y—
3Y0.16

Price change analysis

↑ 15.2%
Over 1 Month
LowHigh
18.5922.62
↓ -60.0%
Over 3 Months
LowHigh
18.5922.83
↓ -60.0%
Over 6 Months
LowHigh
18.5922.83
↓ -60.0%
Over 1 Year
LowHigh
18.5922.83
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (Sept. 30, 2022)
₹2 Cr
Net profit (Sept. 30, 2022)
₹-2 Cr
Basic EPS (Sept. 30, 2022)
₹

Ranks #None of 62 in Healthcare Services by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Mar 2026
  • Promoter72.81%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 72.81% in Mar 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
13 Mar 2025 EMILY BOSCO MENEZES Bulk Buy 63,750 30.7500 BSE
13 Mar 2025 BOSCO ARMANDO MENEZES Bulk Sell 63,750 30.7500 BSE
25 Jun 2018 INVENTURE GROWTH & SECURITIES LTD. Bulk Sell 63,000 48.1300 BSE
25 Oct 2017 NISHAJAYESHCHOKSHI Bulk Sell 3,000 54.3000 BSE
25 Oct 2017 NISHAJAYESHCHOKSHI Bulk Buy 30,000 59.7500 BSE
25 Oct 2017 KANCHUSTAMBHAM TRILEKHA Bulk Sell 54,000 59.2100 BSE
25 Oct 2017 M REKHA Bulk Buy 57,000 50.9000 BSE
25 Oct 2017 SACHIN BHUWALKA (HUF) Bulk Buy 81,000 53.8300 BSE
25 Oct 2017 INVENTURE GROWTH & SECURITIES LTD. Bulk Sell 384,000 52.6900 BSE
24 Oct 2017 S N SRINIVASA MURTHY Bulk Sell 36,000 52.9600 BSE

All bulk and block deals →

Corporate Announcements

All 4 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 AGM/EGM Vanta Bioscience Ltd - 540729 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 AGM/EGM Vanta Bioscience Ltd - 540729 - Shareholder Meeting / Postal Ballot-Outcome of AGM
29 Sep 2026 Insider Trading / SAST Vanta Bioscience Ltd - 540729 - Closure of Trading Window
5 Sep 2026 Others Vanta Bioscience Ltd - 540729 - Board Meeting Outcome for Outcome Of Board Meeting Held On 05.09.2026 - 10Th Annual General Meeting ('AGM') To Be Held On 30.09.2026

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

  • Thin net profit margin (-88.4%)

Opportunities

  • RSI in oversold territory (28.4) -- a technical rebound zone

Threats

  • Down 60.0% over the past year

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Vanta Bioscience Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.